Paolo Tarantino/X
Dec 10, 2024, 07:40
Paolo Tarantino: Upcoming SABCS24 session on the future of ADCs
Paolo Tarantino, Research Fellow at the Dana-Farber Cancer Institute, shared on LinkedIn:
“Small preview from Wednesday’s SABCS24 session on the future of ADCs
Question: what do all these ongoing phase 3 ADC trials have in common?
Dec 11, 3.30 pm, Hemisfair Ballroom 1-2.”
Dr. Paolo Tarantino, MD, is pursuing an advanced research fellowship at Dana-Farber Cancer Institute and Harvard Medical School, concurrently working towards a PhD in clinical research at the University of Milan.
His research focuses on exploring the HER2 oncoprotein, investigating the emerging HER2-low subgroup of breast tumors, and developing novel antibody-drug conjugates targeting every subtype of breast cancer.
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Feb 9, 2025, 18:29
Feb 9, 2025, 18:21
Feb 9, 2025, 18:09
Feb 9, 2025, 18:06
Feb 9, 2025, 17:54
Feb 9, 2025, 17:24
Feb 9, 2025, 17:14